Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Teva Snaps Up Compliance Tracking Startup Gecko

By HospiMedica International staff writers
Posted on 04 Oct 2015
Teva Pharmaceutical Industries (Teva; Petah Tikva, Israel) has acquired respiratory disease compliance startup Gecko Health Innovations (Gecko; Cambridge, MA, USA) for an undisclosed sum. More...


The purchase positions Teva with in-house medication compliance tracking capabilities for consumer use, leveraging a technology largely reserved for clinical trials into one available for everyday use by its customers. Gecko, founded in 2012, has focused so far on chronic obstructive pulmonary disease (COPD) and asthma compliance via its flagship product, CareTRx, which is comprised of a hardware device which attaches to most metered-dose inhalers (MDIs), as well as a software program which synchronizes and stores data through an app-based user interface to the cloud.

Together with Gecko Health Innovations, Teva will further explore new ways to apply the CareTRx technology to its robust pipeline and portfolio of respiratory products, with the goal of enhancing clinical outcomes for patients. The purchase also takes out of play one of a handful of high-profile startups in the medical compliance market, which include Propeller Health (Madison, WI, USA), whose sensor and digital health platform were approved for use with the in GlaxoSmithKline (GSK; London, United Kingdom) Diskus dry powder inhaler for asthma and COPD.

“The acquisition of Gecko Health Innovations further enhances Teva's ability to develop and deliver truly patient-centered solutions by utilizing eConnected, data-driven technology to improve the management of respiratory diseases,” said Rob Koremans, MD, President and CEO of Teva Global Specialty Medicines.

“During the last three years, we have designed and built a system to support respiratory disease management by intuitively connecting caregivers, patients, and families,” said Yechiel Engelhard, MD, CEO and Founder of Gecko Health Innovations. “Our vision was to connect chronic medication management into one platform, leveraging this information to support and empower patients by partnering with leading players in the healthcare and pharmaceutical industries. We are very excited to realize this vision as it aligns to Teva's focus on innovative patient solutions.”

Related Links:

Teva Pharmaceutical Industries
Gecko Health Innovations
Propeller Health



Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Enteral Feeding Pump
SENTINELplus
PACS Workstation
PaxeraView PRO
Medical Monitor
VITALMAX 4100SL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.